Today: 7 February 2026
Subscribe
Browse Category

NYSE:AEO News 3 December 2025

American Eagle Outfitters (AEO) Stock Soars After Q3 Beat and Holiday Upgrade: Latest News, Analyst Targets and 2026 Outlook

American Eagle Outfitters (AEO) Stock Soars After Q3 Beat and Holiday Upgrade: Latest News, Analyst Targets and 2026 Outlook

American Eagle Outfitters, Inc. (NYSE: AEO) stock is having a breakout session on December 3, 2025, surging after the retailer delivered stronger‑than‑expected third‑quarter results and raised its holiday outlook. By late Wednesday trading, AEO was changing hands around $24, up roughly 14–15% on the day, near fresh 52‑week highs and more than double its lows from earlier in the year. StockAnalysis+1 Below is a full rundown of all the key news, forecasts, and analyses as of December 3, 2025, and what they may mean for American Eagle Outfitters stock going into 2026. AEO Stock Today: Why Shares Are Jumping Multiple
3 December 2025
··

Stock Market Today

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

Philip Morris stock price: PM steadies near $183 after upbeat 2026 forecast puts Zyn battle back in view

7 February 2026
New York, Feb 7, 2026, 15:18 EST — Market closed. Philip Morris International shares last stood at $182.81, up 0.45% from the prior session, after the company laid out a higher 2026 profit outlook tied to its nicotine pouch business. (Reuters) That matters now because the stock has become a referendum on whether smoke-free products can keep carrying earnings while the category gets crowded. Zyn is the big swing factor, and traders are watching for any sign that volume gains are coming at the cost of pricing power. With U.S. markets shut for the weekend, the next test comes at
AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop